ClinicalTrials.gg
Active, not recruitingNCT06226571Updated Sep 16, 2026

A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias

A Phase 1 interventional study of Revumenib and Chemotherapy Regimen in Acute Myeloid Leukemias, sponsored by Syndax Pharmaceuticals. Active, not recruiting at 48 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Syndax Pharmaceuticals · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing revumenib in Leukemia, Myeloid, Acute — 16 open to participants now, 17 under way, 3 of them phase 3. revumenib · Leukemia, Myeloid, Acute.

Enrollment
6th of 18
96 · median 41
Started
2024
with 6 others
Phase 1
8 of 18
6 open now
Primary completion
2027-02
later than 4 of 16 live
Registered
6th of 18
by date
Lead sponsor
4 of 18
Syndax Pharmaceuticals

Among the 18 studies testing revumenib in Leukemia, Myeloid, Acute, this one is the 6th largest by enrollment, is one of 7 that started in 2024, is one of 8 in phase 1, reaches primary completion later than 4 of the 16 other live ones, and was the 6th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

16 of the 18 studies testing revumenib in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About revumenib

revumenib: first FDA approval 2024 (REVUFORJ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing revumenib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of revumenib in combination with intensive chemotherapy in participants with newly diagnosed acute myeloid leukemia (AML) harboring alterations in KMT2A, NPM1, or NUP98 genes.

Read the detailed description

The Dose Escalation portion of this study will identify the maximum tolerated dose, or if different, the recommended Phase 2 dose of revumenib to be used in combination with intensive chemotherapy and in maintenance monotherapy following intensive chemotherapy in participants with newly diagnosed AML harboring alterations in KMT2A, NPM1, or NUP98 genes.

In the Dose Expansion portion of the study, safety and preliminary efficacy of revumenib may be explored in expansion cohorts at tolerated dose levels.

In both Dose Escalation and Dose Expansion, the treatment period will consist of an induction phase (up to 2 cycles), a consolidation phase (up to 4 cycles and could include hematopoietic stem cell transplant for participants who are transplant eligible and have an available donor), and a maintenance monotherapy phase with revumenib. The cycle duration will be 28 days.

03

Conditions studied

  • Acute Myeloid Leukemias

Keywords

  • SNDX-5613
  • Lysine-specific Methyltransferase 2A
  • KMT2A/MLL
  • Nucleophosmin 1
  • NPM1
  • Nucleoporin 98
  • NUP98
  • AML
  • revumenib
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Established, confirmed diagnosis of AML by World Health Organization 2022 criteria.
  • Newly diagnosed and previously untreated AML and eligible to receive intensive chemotherapy.
  • KMT2Ar, NPM1m, or NUP98r mutations identified by local laboratory prior to the first dose of revumenib.
  • performance status ≤2 and ≤1 if >65 years old.
  • Adequate liver, kidney, and cardiac function.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of acute promyelocytic leukemia.
  • Clinically active central nervous system leukemia (blasts detected in cerebrospinal fluid, radiographic or clinical signs and symptoms).
  • Fridericia's interval (QTcF) >450 milliseconds (average of triplicate), diagnosis or suspicion of Long QT syndrome or family history of Long QT syndrome.
  • Any gastrointestinal issue of the upper gastrointestinal tract that might affect oral drug absorption or ingestion.
  • Cirrhosis with a score of B or C.
  • Any of the following within the 6 months prior to study entry: myocardial infarction, uncontrolled/unstable angina, congestive heart failure ( Classification Class ≥II), life-threatening, uncontrolled arrhythmia, cerebrovascular accident, or .
  • , , or -positive with detectable viral load.
  • Documented active, uncontrolled infection.
  • Uncontrolled disseminated intravascular coagulation.
  • Lactating/breast feeding or pregnant.
  • Use of prohibited concomitant chemotherapy, radiation therapy, or immunotherapy.
  • Use of strong inducers or inhibitors (except for Itraconazole, Ketoconazole, Posaconazole, or Voriconazole).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Revumenib

    Dose Escalation: * Induction: Sequential cohorts of escalating dose levels of revumenib with chemotherapy regimen. * Consolidation: Cohorts will receive high-dose cytarabine (HiDAC) chemotherapy followed by revumenib. * Maintenance Monotherapy: Cohorts will receive revumenib Dose Expansion: * Induction: revumenib at tolerated dose level with chemotherapy regimen. * Consolidation: Cohorts will receive revumenib with chemotherapy regimen and HiDAC. * Maintenance Monotherapy: Cohorts will receive revumenib.

    Drug: Revumenib · Drug: Chemotherapy Regimen · Drug: HiDAC

Interventions

  • Participants will receive revumenib orally during Induction, Consolidation, and Maintenance until meeting criteria for discontinuation.

    Also known as: SNDX-5613

  • DrugChemotherapy Regimen

    Induction: Participants will receive an intravenous (IV), 2-drug combination of cytarabine and either daunorubicin or idarubicin.

  • DrugHiDAC

    Consolidation: Participants will receive HiDAC IV.

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Number of Participants with Dose-limiting Toxicities

    Time frame: Up to Day 42

  2. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Day 1 through 30 days after final dose (up to approximately 3 years)

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of Revumenib and its Major Metabolite

    Time frame: Predose through Day 15

  2. Area Under the Plasma Concentration Versus Time Curve From Time 0 to t (AUC0-t) of Revumenib and its Major Metabolite

    Time frame: Predose through Day 15

07

Study locations

48 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Feb 2027, 33 months after the start.

Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 33 months is below that.

Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2024
First posted
Jan 26, 2024
StartActual
May 21, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06226571
Responsible party
Sponsor
First posted
Jan 26, 2024
Start date
May 21, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Sep 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Revumenib

Start the discussion